Gastroenterologia y hepatologia最新文献

{"title":"Thromboembolic phenomena in inflammatory bowel disease and risk with JAK inhibitor treatments.","authors":"José Luis Rueda García, José Manuel Benitez, Iria Baston Rey, Margalida Calafat Sard, Cristina Suárez Ferrer","doi":"10.1016/j.gastrohep.2024.502257","DOIUrl":"10.1016/j.gastrohep.2024.502257","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502257"},"PeriodicalIF":2.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy.","authors":"Mahrez Fissah, Adel Rechach, Meriem Charifi, Farouk Menzou, Said Taharboucht, Messaouda Djouhri, Leila Talbi, Nadia Touati, Lamine Atif, Mehdi Rabhia, Ahcene Chibane","doi":"10.1016/j.gastrohep.2024.502252","DOIUrl":"10.1016/j.gastrohep.2024.502252","url":null,"abstract":"<p><strong>Introduction: </strong>Recent studies have demonstrated the growing interest in cardiovascular risk in Crohn's disease (CD), the aim of our work is to highlight the need for research into the frequency of arterial stiffness (AS) and its link with certain associated factors, particularly those related to inflammation.</p><p><strong>Materials and methods: </strong>This was a cross-sectional observational study involving 118 patients with CD. Pulse wave velocity (PWV) measured by applanation tonometry was the criterion for calculating AS, the study also investigated the association of AS especially the indicators of inflammation, as well as the impact of anti-TNF alpha therapy on AS.</p><p><strong>Results: </strong>The prevalence of AS, after adjustment for age and blood pressure level reached more than a quarter of patients compared to the cardiovascular risk which was low. The factors that were strongly associated with AS were age, systolic and diastolic blood pressure. Two parameters related to inflammation emerged as having a highly significant link after multivariate analysis: recurrence in the last year and length of disease with a p=0.008, and an OR of 5 and 9 successively. Patients treated with anti-TNF alpha had a significant reduction in PWV.</p><p><strong>Conclusion: </strong>The prevalence of AS reached more than a quarter of patients with CD, the duration and recurrence rate of CD appear to be factors linked to inflammation. Treatment with anti-TNF alpha seems to slow down PWV in these patients.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502252"},"PeriodicalIF":2.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leishmania colitis: An uncommon cause of gastrointestinal bleeding in an immunosuppressed patient.","authors":"Francisco Vara-Luiz, Helena Pires, Ivo Mendes, Carolina Palma, Eduardo Fernandes, Ana Elisa Teles, Francisco Martins do Vale, Marta Patita, Jorge Fonseca, Pedro Pinto-Marques","doi":"10.1016/j.gastrohep.2024.502254","DOIUrl":"10.1016/j.gastrohep.2024.502254","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502254"},"PeriodicalIF":2.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing outcomes with maintenance IV UST in highly bio-exposed patients with IBD. Efficacy and adjusted regimen in real world.","authors":"Alejandro Mínguez, Elena Coello, Alejandro Garrido, Paula Ripoll, María Gomez, Mariam Aguas, Marisa Iborra, Elena Cerrillo, Lluis Tortosa, Virginia Bayarri, Noemí Bueno, Maria José Fernández, Remedios Marqués, Pilar Nos, Guillermo Bastida","doi":"10.1016/j.gastrohep.2024.502253","DOIUrl":"10.1016/j.gastrohep.2024.502253","url":null,"abstract":"<p><strong>Background and aims: </strong>Ustekinumab is an effective treatment for inflammatory bowel diseases. However, some patients do not respond to conventional doses. The aim of the study was to evaluate the effectiveness of intravenous maintenance ustekinumab in patients with secondary failure.</p><p><strong>Methods: </strong>Single-center, retrospective study in adult patients with intravenous maintenance ustekinumab. The reduction of biochemical activity markers, ustekinumab trough levels and clinical indices of activity were evaluated. Biological remission was defined as the percentage decrease fecal calprotectin ≥80% and/or final fecal calprotectin ≤250 and C reactive protein <5mg/L.</p><p><strong>Results: </strong>Thirty-one patients were included: Crohn's disease 77.4%. All included patients were bio-exposed and 61.3% had carried ≥2 biologics. Pre-intravenous maintenance mean Harvey-Bradshaw Index was 6.5±4.38 vs 5±3.1 at week 8 (p=0.024) vs 4.1±3.1 at week 24 (p=0.019). The median ustekinumab trough level pre-intravenous maintenance was 1.40μg/ml [IQR 2.3] vs 5.35μg/ml [IQR 4.1] at week 8 (p<0.001) vs 4.8μg/ml [IQR 3.9] at week 24 (p<0.001). The pre-intravenous maintenance median fecal calprotectin was 809μg/g [IQR: 2256] vs 423μg/g [IQR: 999] at week 8 (p=0.025) vs 333μg/g [508] (p=0.001) at week 24. At the end of follow-up 48% went into biological remission. The presence of perianal disease was associated with lower biological remission (70.6% vs 27.3%, p=0.025). Median intravenous ustekinumab maintenance time was 8.55 [IQR 23.9] months. In 83.9% of patients no serious infections or malignancy were documented.</p><p><strong>Conclusions: </strong>The use of maintenance intravenous ustekinumab appears to be an effective and safe strategy that can be evaluated as a salvage treatment especially in highly bio-exposed patients.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502253"},"PeriodicalIF":2.2,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D.","authors":"María Buti, Jose Luis Calleja, Miguel Ángel Rodríguez, Raquel Domínguez-Hernández, Helena Cantero, Nataly Espinoza-Cámac, Miguel Ángel Casado","doi":"10.1016/j.gastrohep.2024.502241","DOIUrl":"https://doi.org/10.1016/j.gastrohep.2024.502241","url":null,"abstract":"<p><strong>Background/aims: </strong>Bulevirtide (Hepcludex®) is the first drug approved for the treatment of chronic hepatitis D (CHD), unlike the current off-label treatment (PEG-IFN-α), limited in clinical practice and associated with post-treatment relapses. In a hypothetical cohort of CHD patients in Spain, the study aim was to compare the efficiency of bulevirtide with PEG-IFN-α in terms of clinical events avoided and associated cost savings.</p><p><strong>Methods: </strong>A validated economic model reflecting the natural history of the disease was used to project lifetime liver complications and costs for two hypothetical cohorts treated with bulevirtide or PEG-IFN-α. The model considered progression to complications such as decompensated cirrhosis (DCC), hepatocellular carcinoma (HCC), liver transplantation (LT), and death. The efficacy rates used at 24 and 48 weeks were defined as the combined response rate for bulevirtide and undetectable HDV RNA to PEG-IFN-α. The numbers of clinic events and associated costs were evaluated from the perspective of the National Healthcare System.</p><p><strong>Results: </strong>In a hypothetical cohort of 3882 patients, bulevirtide reduced the numbers of complications events in comparison to PEG-IFN-α (152 DCC, 113 HCC, 11 LT, and 321 deaths over a lifetime). This was associated with a reduction of event-related costs of €11,837,044 (DCC €1,138,059; HCC €1,503,583; LT €7,834,291; and death €1,361,111).</p><p><strong>Conclusion: </strong>In patients with CHD, bulevirtide could prevent a significant number of clinical events compared to PEG-IFN-α and contribute to cost savings through these reduction in liver complications. Further testing for hepatitis D virus is needed so that more patients can benefit from bulevirtide.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502241"},"PeriodicalIF":2.2,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142284420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for advanced liver disease incorporating the use of transitional elastography in primary care.","authors":"Mar Noguerol Álvarez, Ma Paz Valer López Fando, Carolina Torrijos Bravo, Ma Carmen Gómez Ortiz, Belén Piqueras Alcohol, Antonio Guardiola Arévalo, Gema De la Poza Gómez, Zahara Pascual García, Sandra Rey Rodríguez, Raquel Iglesias Sigüenza, Esther Ledesma Estévez, Susana Parra Román, María Gómez Suárez, Angela Pérez San Juan, Miriam Ruiz Romero, Laura Martínez Vega, Beatriz López Uriarte, Francisco Góngora Maldonado, Blanca Martín Porras, Pilar Serrano Gismero, Elvira Rubio Benito, Gloria Viñas Fernández, Ma José Rojas Giraldo, Ana Ma Hernández Sánchez, María Alonso Ovies, Gema María Saiz Ladera, Nuria Martín Peña, Jesús Fernández Horcajuelo, Victoria Llinares Gómez, José Francisco Sánchez Mateos, Elena Polentinos Castro, Ricardo Rodríguez Barrientos, Manuel Carbajo Ariza, Greta Amat Baeza, Fernando Bermejo San José","doi":"10.1016/j.gastrohep.2024.502242","DOIUrl":"10.1016/j.gastrohep.2024.502242","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the proportion of patients with liver fibrosis in at-risk populations in primary care (PC). To know the agreement between FIB-4 and transitional elastography (TE), interobserver agreement between PC and hospital care (HC) in TE, and associated risk Factors (RF).</p><p><strong>Methods: </strong>Observational, descriptive, cross-sectional study in ≥16 years of age with RF for chronic liver disease. Sex and age, RF (alteration of liver tests [LT], metabolic syndrome, diabetes, obesity, alcohol consumption, hepatic steatosis), and FIB-4, controlled attenuation parameter and TE in PC and in HC, were collected. According to a consensus algorithm, vibration-controlled TE was performed in PC in patients with FIB-4≥1,3, and those with measurement ≥8kPa were referred to HC.</p><p><strong>Results: </strong>326 patients were studied. 71% were not referred to HC, due to liver stiffness <8kPa. 83 of the 95 derivations did TE in HC. 45 (54%) had TE ≥8, and 25 (30%) ≥12. The proportion of patients with stiffness ≥8kPa was 13,8% (45/326) and ≥12kPa, 7,6% (25/326). The predictive values of the FIB-4 were low. The interobserver correlation coefficient between TE in PC and HC was 0,433. Variables associated with TE ≥8 in PC: LT alteration, diabetes and steatosis. With TE ≥12: LT alteration, diabetes and obesity.</p><p><strong>Predictor variables: </strong>LT alteration and obesity.</p><p><strong>Conclusions: </strong>The study supports the sequential performance of serum indices and TE as a screening for fibrosis in the at-risk population in PC, which allows a reduction in the percentage of patients referred to AH, and a better stratification of risk patients.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502242"},"PeriodicalIF":2.2,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venetoclax as a possible chemopreventive agent in adenomatous polyposis: A case report.","authors":"Cautar El Maimouni, Maria Daca-Alvarez, Julio Delgado, Maria Pellisé, Francesc Balaguer","doi":"10.1016/j.gastrohep.2024.502239","DOIUrl":"10.1016/j.gastrohep.2024.502239","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502239"},"PeriodicalIF":2.2,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142106729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cobblestone Oesophagus: A Rare Form of Severe Oesophagitis in Scleroderma.","authors":"Raúl Fernández García, Maria Del Carmen Fernández Cano, Eduardo Redondo Cerezo","doi":"10.1016/j.gastrohep.2024.502238","DOIUrl":"10.1016/j.gastrohep.2024.502238","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502238"},"PeriodicalIF":2.2,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descriptive observational study on the use of virtual reality in patients with inflammatory bowel disease undergoing biological treatment.","authors":"Raúl José Díaz Molina, Carlos Comesaña Castellar, Joan Crespí Rigo, Catalina Radu Tomsa, Patricia Quesada Bauzá, Isabel Porcel Corra, Pau Sendra Rumbeu, Vanesa Royo Escosa, María Dolores Herrera González, Eva Puchol Segarra, Daniel Ginard Vicens","doi":"10.1016/j.gastrohep.2024.502236","DOIUrl":"10.1016/j.gastrohep.2024.502236","url":null,"abstract":"<p><strong>Background: </strong>Virtual reality (VR) is a neurosensory experience in which simulated spaces a person has the sensation of being able to function within them. Some patients with inflammatory bowel disease (IBD) receive intravenous biological treatments in an Adult Day Hospital (ADH) regime. VR has been used in some fields of medicine, demonstrating its usefulness in reducing negative symptoms. However, we do not have any literature showing the applicability in real clinical practice of VR in IBD.</p><p><strong>Methods: </strong>Descriptive observational pilot study based on an initial cohort of 87 patients that were obtained from the ADH of the IBD Unit. Satisfaction and acceptance of VR through the use of 3D glasses and the reduction of negative symptoms during intravenous biological treatment in patients with IBD in ADH have been assessed.</p><p><strong>Results: </strong>43 patients (52.4%) used VR and completed the study. In the comparative analysis of the results of the questionnaires before and after the use of VR, a statistically significant improvement was observed in the patients' view on the ability of VR to achieve a reduction in stress (65% patients improve; p: 0.0021) and pain (VAS, 54% p. improve; p<0.05) during treatment. Likewise, with the applicability of VR in other areas of medicine (53%; p: 0.05) and with the possibility of improving well-being during the stay in the ADH (56%; p: 0.0014). No side effects were reported with the use of the 3D glasses.</p><p><strong>Conclusions: </strong>VR is a useful complementary tool to improve the stay of patients with IBD on ADH during intravenous treatment.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502236"},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tips and tricks for writing a manuscript to publish in a biomedical journal.","authors":"Javier P Gisbert, María Chaparro","doi":"10.1016/j.gastrohep.2024.502237","DOIUrl":"10.1016/j.gastrohep.2024.502237","url":null,"abstract":"<p><p>Science barely exists until it is published. It is only then that the information surpasses the limits of the author and can be shared by the scientific community. Although scientific articles must follow a rigidly defined structure, there is still room to tell a fascinating story, one that clearly conveys the science and is, at the same time, enjoyable for the reader. To do this, we must use the attributes that characterize good scientific style, with simple, clear, precise, direct, rigorous, and consistent language. Authorship implies authenticity and authority, and considering a researcher as an author entails rights and responsibilities. Scientific writing is not easy, it requires patience and practice; learning to write well is a lifelong task. With the philosophy that most of the qualities required to proficiently write a scientific article depend on attitude, and can be learned and improved upon, in this manuscript we will share with the reader a series of recommendations (based on our own experiences, both positive and negative), which we consider important for writing and successfully publishing. We will focus on the so-called «original» articles (as opposed to review articles, although many of the recommendations presented are applicable to both). Our main purpose is to encourage researchers to take the necessary step and face the challenge of becoming authors of their own scientific articles and successfully publishing their research.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502237"},"PeriodicalIF":2.2,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}